Diabetes Pen Market Report 2026

The diabetes pen market size has grown strongly in recent years. It will grow from $31.04 billion in 2025 to $32.98 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing insulin-dependent diabetic population, limitations of vial and syringe methods, rising awareness of self-injection devices, hospital-driven insulin therapy, availability of prefilled insulin formulations.

The diabetes pen market size is expected to see strong growth in the next few years. It will grow to $42.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in smart insulin pen adoption, rising homecare diabetes management, technological advancements in pen needles, increasing patient adherence focus, expansion of digital diabetes ecosystems. Major trends in the forecast period include growing adoption of disposable insulin pens, rising preference for user-friendly injection devices, expansion of smart insulin pen technologies, increasing focus on patient convenience and portability, growing demand for home-based insulin administration.

The growing prevalence of diabetes worldwide is expected to drive the growth of the diabetes pen market in the coming years. Diabetes is a group of chronic metabolic disorders characterized by persistently high blood glucose levels. Diabetes pens are insulin delivery devices that enable more precise dosing, improved treatment adherence, and a lower risk of hypoglycemia. These pens are also associated with reduced injection-site discomfort and are widely preferred by individuals with diabetes who require insulin therapy. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international non-profit organization representing national diabetes associations, approximately 589 million adults aged 20-79 were living with diabetes globally, a figure projected to rise to 853 million by 2050. Therefore, the increasing global prevalence of diabetes is driving the expansion of the diabetes pen market.

Major companies operating in the diabetes pen market are increasingly focusing on integrating smart-connected solutions, such as digital insulin delivery technologies, to improve treatment monitoring and support medication adherence. Digital insulin delivery technologies are connected add-on devices that record insulin dosing information from pens and transmit the data to compatible mobile applications, enabling features such as automated dose tracking, real-time therapy insights, and adherence monitoring. For instance, in January 2024, BIOCORP, a France-based medical device company, received U.S. Food and Drug Administration (FDA) 510(k) clearance for SoloSmart, a smart cap technology designed to capture insulin dose data from Sanofi’s SoloStar disposable pens and transmit it via a dedicated mobile application. The system offers automatic injection data capture and Bluetooth-enabled data transfer, helping improve adherence, data accuracy, and the efficiency of digital diabetes management.

In September 2023, Abbott Laboratories, a US-based medical devices and healthcare company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition is intended to strengthen Abbott’s presence in the diabetes market by expanding its product portfolio and gaining access to Bigfoot Biomedical’s established customer base. The transaction aims to enhance diabetes care and patient outcomes by combining the technological expertise and solutions of both companies. Bigfoot Biomedical Inc. is a US-based company specializing in diabetes management systems, including insulin pens and smart pen cap technologies.

Major companies operating in the diabetes pen market are F. Hoffmann La Roche AG, Sanofi S.A., Astra Zeneca plc, Eli Lilly and Company, Novo Nordisk A/S, BD (Becton Dickinson and Company), Teruma Medical Corporation, YPSOMED Holding AG, Owen Mumford Ltd., WOCKHARDT, Nipro Europe Group Companies, Biocon, Jiangsu Delfu Medical Device Co., HTL‑STREFA Inc., Medtronic plc, Emperra GmbH, Pendiq GmbH, Asahi Kasei Medical Co Ltd, B Braun Melsungen AG, Gan & Lee Pharmaceuticals, Insulet Corporation, Haselmeier.

North America was the largest region in the diabetes pen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes pen market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes pen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetes pen market by increasing costs of imported pen components, insulin cartridges, needles, and medical-grade plastics. North America and Europe are most affected due to reliance on imported insulin delivery devices, while Asia-Pacific faces higher manufacturing input costs. These tariffs are raising device prices for patients. However, they are also supporting local manufacturing, regional assembly of insulin pens, and improved supply chain resilience for diabetes care devices.

The diabetes pen market research report is one of a series of new reports that provides diabetes pen market statistics, including diabetes pen industry global market size, regional shares, competitors with a diabetes pen market share, detailed diabetes pen market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes pen industry. This diabetes pen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A diabetes pen is a medical device used to deliver insulin to individuals with diabetes and serves as an alternative to traditional methods such as vials and syringes. It is designed as a convenient and user-friendly solution that enables people with diabetes to self-administer insulin in a more discreet and portable way.

The main products in the diabetes pen market include insulin pens and pen needles. Insulin pens are widely used blood glucose management tools that allow accurate and easy measurement and delivery of insulin. They are available as reusable and disposable injection pens and are used for administering insulin, glucagon-like peptide-1, growth hormones, fertility treatments, and osteoporosis therapies. These products are distributed through channels such as retail pharmacies, online medical stores, and diabetes clinics.

The diabetes pen market includes revenues earned by entities by insulin delivery, cartridge or prefilled, and dosing mechanism. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetes pen market also includes sales of fixed-dose pens, multi-dose pens, and adjustable-dose pens for providing select the desired amount of insulin to be injected services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.